FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to using cortexolone 17α-benzoate in treating a malignant disease, which is a solid tumour. Invention also relates to pharmaceutical compositions, to methods of treating a tumour disease, to a method of treating a glucocorticoid mediated disease or disorder.
EFFECT: technical result is application of cortex salon 17α-benzoate in treating a glucocorticoid mediated disease or disorder.
39 cl, 18 dwg, 29 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN TREATMENT OF TUMOURS | 2015 |
|
RU2712950C2 |
| 17A, 21-DIESTERS OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2821529C2 |
| METHOD OF PREVENTION AND/OR TREATMENT OF CANCEROUS DISEASES | 2006 |
|
RU2480201C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| SUPPRESSION OF CANCER METASTASES | 2010 |
|
RU2571502C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
